Literature DB >> 26300042

Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.

Julia D Suerth1, Michael A Morgan1, Stephan Kloess2, Dirk Heckl1, Christine Neudörfl3, Christine S Falk3, Ulrike Koehl2, Axel Schambach4,5.   

Abstract

UNLABELLED: Natural killer (NK) cells play an important role in tumor immunotherapy with their unique capability of killing transformed cells without the need for prior sensitization and without major histocompatibility complex (MHC)/peptide restriction. However, tumor cells can escape NK cell cytotoxicity by various tumor immune escape mechanisms. To overcome these escape mechanisms, NK cells can be modified to express chimeric antigen receptors (CARs), enhancing their tumor-specific cytotoxicity. To determine the most efficacious method to modify human NK cells, we compared different retroviral vector systems, retroviral pseudotypes, and transduction protocols. Using optimized transduction conditions, the highest transduction levels (up to 60%) were achieved with alpharetroviral vectors. Alpharetroviral-modified primary human NK cells exhibited no alteration in receptor expression and had similar degranulation activity as untransduced NK cells, thus demonstrating that alpharetroviral modification did not negatively affect NK cell cytotoxicity. Transduction of NK cells with an alpharetroviral vector containing a CD19 CAR expression cassette selectively enhanced NK cell cytotoxicity towards CD19-expressing leukemia cells, achieving nearly complete elimination of leukemia cells after 48 h. Taken together, alpharetroviral vectors are promising tools for NK cell-mediated cancer immunotherapy applications. KEY MESSAGES: Efficient modification of human NK cells using alpharetroviral vectors. Anti-CD19-CAR-NK cells exhibited improved cytotoxicity towards CD19(+) leukemia cells. Alpharetroviral vectors are promising tools for immunotherapy applications using NK cells.

Entities:  

Keywords:  Alpharetrovirus; Chimeric antigen receptor; Gene therapy; Immunotherapy; Leukemia; Natural killer cells

Mesh:

Substances:

Year:  2015        PMID: 26300042     DOI: 10.1007/s00109-015-1327-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  46 in total

1.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

Review 2.  Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.

Authors:  Beatriz Sanchez-Correa; Sara Morgado; Inmaculada Gayoso; Juan M Bergua; Javier G Casado; Maria Jose Arcos; Maria Luisa Bengochea; Esther Duran; Rafael Solana; Raquel Tarazona
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

3.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Authors:  Cor H J Lamers; Ralph Willemsen; Pascal van Elzakker; Sabine van Steenbergen-Langeveld; Marieke Broertjes; Jeannette Oosterwijk-Wakka; Egbert Oosterwijk; Stefan Sleijfer; Reno Debets; Jan W Gratama
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

4.  IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.

Authors:  Ulrike Koehl; Jan Sörensen; Ruth Esser; Stefanie Zimmermann; Hans Peter Grüttner; Torsten Tonn; Christian Seidl; Erhard Seifried; Thomas Klingebiel; Dirk Schwabe
Journal:  Blood Cells Mol Dis       Date:  2004 Nov-Dec       Impact factor: 3.039

5.  Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.

Authors:  A Hombach; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2010-06-17       Impact factor: 5.250

6.  Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Jens Bohne; Saurabh Chandra; Elke Will; Geoffrey P Margison; David A Williams; Christopher Baum
Journal:  Mol Ther       Date:  2005-10-12       Impact factor: 11.454

7.  Self-inactivating alpharetroviral vectors with a split-packaging design.

Authors:  Julia D Suerth; Tobias Maetzig; Melanie Galla; Christopher Baum; Axel Schambach
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

8.  Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

Authors:  Virginie Sandrin; Bertrand Boson; Patrick Salmon; Wilfried Gay; Didier Nègre; Roger Le Grand; Didier Trono; François-Loïc Cosset
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 9.  Advantages and applications of CAR-expressing natural killer cells.

Authors:  Wolfgang Glienke; Ruth Esser; Christoph Priesner; Julia D Suerth; Axel Schambach; Winfried S Wels; Manuel Grez; Stephan Kloess; Lubomir Arseniev; Ulrike Koehl
Journal:  Front Pharmacol       Date:  2015-02-12       Impact factor: 5.810

10.  Are natural killer cells superior CAR drivers?

Authors:  Hans Klingemann
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

View more
  26 in total

Review 1.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

2.  Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

Authors:  D Hoffmann; J W Schott; F K Geis; L Lange; F-J Müller; D Lenz; D Zychlinski; D Steinemann; M Morgan; T Moritz; A Schambach
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

Review 3.  The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.

Authors:  Jake Moscarelli; David Zahavi; Rachael Maynard; Louis M Weiner
Journal:  Transplant Cell Ther       Date:  2022-07-03

4.  Tumor immunotherapy: New aspects of natural killer cells.

Authors:  Yangxi Li; Rui Sun
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 5.  Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells.

Authors:  Nicolas Dulphy; Anne-Sophie Chrétien; Zena Khaznadar; Cyril Fauriat; Arash Nanbakhsh; Anne Caignard; Salem Chouaib; Daniel Olive; Antoine Toubert
Journal:  Front Immunol       Date:  2016-03-09       Impact factor: 7.561

6.  Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies.

Authors:  Erhard Hofer; Ulrike Koehl
Journal:  Front Immunol       Date:  2017-07-12       Impact factor: 7.561

Review 7.  Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.

Authors:  Olaf Oberschmidt; Stephan Kloess; Ulrike Koehl
Journal:  Front Immunol       Date:  2017-06-09       Impact factor: 7.561

8.  Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Charline Sommer; Sebastian Böhlen; Christina Ziemann; Susann Dehmel; Armin Braun; Uta Sandy Tretbar; Stephan Klöß; Axel Schambach; Michael Morgan; Dennis Löffler; Christoph Kämpf; Conny Blumert; Kristin Reiche; Jana Beckmann; Ulla König; Bastian Standfest; Martin Thoma; Gustavo R Makert; Sebastian Ulbert; Uta Kossatz-Böhlert; Ulrike Köhl; Anna Dünkel; Stephan Fricke
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

Review 9.  Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy.

Authors:  Raquel Tarazona; Esther Duran; Rafael Solana
Journal:  Front Immunol       Date:  2016-01-07       Impact factor: 7.561

10.  Immunomodulatory activity of a novel polysaccharide from Lonicera japonica in immunosuppressed mice induced by cyclophosphamide.

Authors:  Xiaonan Zhou; Qun Dong; Xianzhao Kan; Lihong Peng; Xingyu Xu; Yun Fang; Jialiang Yang
Journal:  PLoS One       Date:  2018-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.